PSC

The Bank of Thailand reaffirms its adherence to integrity and principles to build confidence - good governance in Thailand

Retrieved on: 
Wednesday, April 10, 2024
Element, Government, Central bank, Finance, Corruption, Environment, Thought, Risk, Ethics, Bank, MPC, PSC, Policy, Human, Conflict of interest, Private sector, NACC, Monetary Policy Committee, Kingdom, News, Person, Virtue, Guideline

Anything we do or think, we have to be able to explain why we act or think this way," she noted.

Key Points: 
  • Anything we do or think, we have to be able to explain why we act or think this way," she noted.
  • The Bank of Thailand also vows to create transparency in the decision-making process and make it auditable.
  • The decision-making is transparent because there is a data storage and communication system so that it can always be traced back.
  • The NACC is supervised by the NACC Board and has the Office of the NACC as its administrative agency.

Genel Energy PLC: Update on year-end 2023 oil reserves

Retrieved on: 
Wednesday, April 10, 2024
DNO, PSC, Taq Taq, Everette Lee DeGolyer

Genel continues to retain 11.7 MMbbls of these 2P Resources, associated with the Tawke field Enhanced Oil Recovery project, as 2C.

Key Points: 
  • Genel continues to retain 11.7 MMbbls of these 2P Resources, associated with the Tawke field Enhanced Oil Recovery project, as 2C.
  • At Taq Taq (44% working interest, joint operator), gross 2P reserves stood at 23.4 MMbbls at year-end 2023 (23.9 MMbbls at end-2022), following production of 0.5 MMbbls.
  • Genel previously booked 2.8 MMbbls of net 2P reserves at Sarta (30% working interest, operator).
  • The Sarta PSC terminated on 1 December 2023.

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Retrieved on: 
Tuesday, April 2, 2024
Q&A, Primary sclerosing cholangitis, Liver disease, UC, UPMC, KOL, PSC, Doctor of Philosophy, Digestate, CCL24, Clinical trial, Therapy, CMMB, Liver, University of California, Davis, FDA, TEL, Pharmaceutical industry

TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced it will host a live key opinion leader (KOL) virtual event on primary sclerosing cholangitis (PSC) on Wednesday, April 10, 2024 at 10:00 AM ET. To register, click here.

Key Points: 
  • —“Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis” Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development—
    TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced it will host a live key opinion leader (KOL) virtual event on primary sclerosing cholangitis (PSC) on Wednesday, April 10, 2024 at 10:00 AM ET.
  • They will discuss the urgent need for new PSC treatments and emerging developments that could facilitate new drug approvals.
  • Chemomab’s co-founder, CEO & CSO Adi Mor, PhD and CMO Matt Frankel, MD, will provide an overview of the CM-101 Phase 2 PSC clinical trial that will report topline results midyear 2024.
  • CM-101 is a dual mechanism first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein that is a key driver of inflammatory and fibrotic pathways central to PSC and other fibro-inflammatory diseases.

Global Pet Expo 2024 Celebrates Record-Breaking Attendance at the 20th Annual Show

Retrieved on: 
Friday, April 5, 2024
Health, Partnership, Education, APPA, PSC, Global Pet Expo, Trade fair, Orange County Convention Center, PIDA, Sustainability, Greater Orlando, Best in Show, American Pet Products Association

STAMFORD, Conn., April 5, 2024 /PRNewswire/ -- The American Pet Products Association (APPA) and Pet Industry Distributors Association (PIDA) hosted the 20th annual Global Pet Expo on March 20-22, 2024, in Orlando, Fla.

Key Points: 
  • STAMFORD, Conn., April 5, 2024 /PRNewswire/ -- The American Pet Products Association (APPA) and Pet Industry Distributors Association (PIDA) hosted the 20th annual Global Pet Expo on March 20-22, 2024, in Orlando, Fla.
  • Global Pet Expo also gives back to the local pet community through its longstanding partnership with the Pet Alliance of Greater Orlando to collect product donations after each event.
  • "It was exhilarating to see the pet industry come together at Global Pet Expo with record-breaking attendance.
  • Global Pet Expo 2025 will take place on March 26-28, 2025, at the Orange County Convention Center in Orlando, Florida.

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Retrieved on: 
Monday, March 25, 2024
Orphan drug, Primary sclerosing cholangitis, Inflammation, Fast Track, European Patent Organisation, Antibody, PSC, Liver, Liver transplantation, Doctor of Philosophy, CCL24, Fibrosis, Treatment, Therapy, European Patent Convention, CMMB, Patent, Use, Hepatology, FDA, TEL, Pharmaceutical industry

TEL AVIV, Israel, March 25, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today reported that the European Patent Office has granted a new patent for CM-101, Chemomab’s first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive fibrosis and inflammation. CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC). Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.

Key Points: 
  • CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC).
  • Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.
  • The new European patent covers the use of CM-101 and sequence-related anti-CCL24 antibodies for the treatment of hepatic (liver) diseases, including PSC.
  • Unlike other drugs in development for PSC, CM-101 has a unique dual mechanism of action that simultaneously blocks fibrosis and inflammation.

Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
Tuesday, March 12, 2024
Primary sclerosing cholangitis, Patient, PSC, Integrin, IPF, Idiopathic pulmonary fibrosis, European, Therapy, Drug development, Clutch (eggs), Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the implementation of BEACON-IPF as a pivotal, adaptive Phase 2b/3 trial in patients with idiopathic pulmonary fibrosis (IPF). The adaptive design implementation, based on acceptance by the European Union (EU) and other global health authorities, will significantly shorten bexotegrast’s late-stage development compared to a traditional Phase 3 trial. Bexotegrast is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins in clinical development for the treatment of IPF and primary sclerosing cholangitis (PSC).

Key Points: 
  • The adaptive design implementation, based on acceptance by the European Union (EU) and other global health authorities, will significantly shorten bexotegrast’s late-stage development compared to a traditional Phase 3 trial.
  • Bexotegrast is an oral, small molecule, dual-selective inhibitor of αvβ6 and αvβ1 integrins in clinical development for the treatment of IPF and primary sclerosing cholangitis (PSC).
  • “The implementation of BEACON-IPF as an accelerated pivotal, adaptive Phase 2b/3 trial design is another example of our efficient approach to drug development,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant Therapeutics.
  • This facility, along with the Company’s December 31, 2023 cash and cash equivalents of $495.7 million are expected to fund Pliant through 2026.

Lumentum Thought Leaders to Present on Leading Edge Innovations and the Role of Photonics in AI Data Centers at OFC 2024

Retrieved on: 
Friday, March 22, 2024
Apps, Applications, Mobile, Wireless, Technology, Semiconductor, Engineering, Software, Manufacturing, Audio, Video, Networks, Hardware, Cloud, PDT, Research, Optics, Conference, MSA, Optica, PSC, AI, Scalability, ROADM, Photonics, Management

Alan Lowe, CEO and President of Lumentum, will take part in the Optica Executive Forum’s CEO Panel at OFC, discussing the evolution and future of the industry.

Key Points: 
  • Alan Lowe, CEO and President of Lumentum, will take part in the Optica Executive Forum’s CEO Panel at OFC, discussing the evolution and future of the industry.
  • This panel will provide a platform for industry leaders to discuss current challenges, opportunities, and the future of the optical communication industry.
  • This session is scheduled for Wednesday, March 27, 2024, from 5:00 pm to 7:00 pm PDT in Room 15 at OFC.
  • For additional information about Lumentum’s presence at OFC 2024, please visit the official event page at https://www.lumentum.com/en/ofc-2024 or contact the customer service team at [email protected] .

Nubis to Showcase Award-Winning 1.6Tbps Optical Module Optimized for ML/AI Clusters at OFC 2024

Retrieved on: 
Thursday, March 21, 2024
Technology, Mobile, Wireless, Semiconductor, Telecommunications, Networks, Internet, Hardware, Data Management, Artificial Intelligence, NPO, IMEC, OSFP, 2D, Laser, PSC, Communication, PCI Express, AI, Short Course, Workshop, Marketing, Potential, Ecosystem, Product management, Ethernet, TBPS, San Diego Convention Center, Silicon photonics, Generation 6 (NASCAR), Medical device

The company will be showcasing its uniquely scalable XT1600 module made possible by a novel 2D optical-fiber array and highly integrated high-speed silicon photonics.

Key Points: 
  • The company will be showcasing its uniquely scalable XT1600 module made possible by a novel 2D optical-fiber array and highly integrated high-speed silicon photonics.
  • Live demonstrations of the XT1600 carrying Ethernet and PCIe Gen 6 signals will be shown in Nubis’ meeting room MR5510 during Exhibit Hall hours from March 26 – 28.
  • The Nubis optical engine can also be seen operating PCIe Gen 6 traffic with Alphawave Semi’s PipeCORE PHY with PiCORE Controller in both the Nubis room and Alphawave Semi’s room MR5617.
  • Award: Nubis Communications will receive its award from Lightwave Innovation Review in a ceremony on March 25 at 17:00.

Meatable Achieves Landmark Breakthrough In Cultivated Meat Technology, Cuts Production Time To Only 4 Days

Retrieved on: 
Thursday, March 21, 2024
Supply Chain Management, Retail, Specialty, Food, Beverage, Bioreactor, Meat, Farmer, CAPEX, Cell, Environment, PSC, Differentiable function, Water, Multimedia, Animal, Movement, Agriculture

Meatable , an industry-leading food technology company, today announced that it has reached an important milestone in its efforts to produce cultivated meat at scale.

Key Points: 
  • Meatable , an industry-leading food technology company, today announced that it has reached an important milestone in its efforts to produce cultivated meat at scale.
  • This breakthrough will enable the company to produce cultivated meat significantly faster and at lower costs than industry norms, and is therefore an important step towards the commercialization of Meatable’s technology and large-scale production of cultivated meat products more broadly.
  • View the full release here: https://www.businesswire.com/news/home/20240321679210/en/
    Meatable Achieves Landmark Breakthrough In Cultivated Meat Technology, Cuts Production Time To Only 4 Days (Photo: Business Wire)
    The breakthrough, using Meatable’s core patented Opti-Ox technology, confronts the challenges faced by the cultivated meat industry to produce product fast and efficiently in order to scale to commercial levels.
  • With its process enabling movement from “cell-to-sausage” in only four days, Meatable can produce high-quality cultivated meat at a significantly reduced cost.

X-energy Unveils Plant Support Center for Training Xe-100 Advanced Small Modular Reactor Operators

Retrieved on: 
Thursday, March 14, 2024
Education, Other Energy, Utilities, Energy, Nuclear, Training, Human factors and ergonomics, Learning, PSC, Engineering, Plant, Seadrift, Texas, Virtual reality, Renewable energy

X-Energy Reactor Company, LLC (“X-energy” or the “Company”), a leading developer of advanced small modular nuclear reactors and fuel technology for clean energy generation, today opened the first training center for future operators of its Xe-100 advanced small modular reactor.

Key Points: 
  • X-Energy Reactor Company, LLC (“X-energy” or the “Company”), a leading developer of advanced small modular nuclear reactors and fuel technology for clean energy generation, today opened the first training center for future operators of its Xe-100 advanced small modular reactor.
  • Called the Plant Support Center (“PSC”), the 10,000 square foot state-of-the-art facility includes a full-scale plant control room simulator, Reactor Protection System prototype, and virtual reality experience, as well as offices and classrooms.
  • “The opening of X-energy’s first Plant Support Center marks another stride forward to the deployment of our first Xe-100 reactors,” said X-energy CEO, J. Clay Sell.
  • Its groundbreaking technology builds upon years of collaboration with the U.S. Department of Energy programs, including Advanced Reactor Concepts 2015, the Advanced Research Projects Agency–Energy (“ARPA-E”), and the Advanced Reactor Demonstration Program (“ARDP”).